The plasma fractionation market is expected to reach USD 52.58 billion in 2031, up from USD 36.44 billion in 2026, at a CAGR of 7.6% over the forecast period. The market is primarily driven by rising demand for immunoglobulins across immunology and neurology, strategic expansion of plasma collection capacity by market players, and greater use of plasma-derived therapies. Immunoglobulins, including IVIG and SCIG, are widely used to manage primary immunodeficiencies, autoimmune disorders, and neurological conditions, supporting sustained demand for plasma-derived products. In addition, companies are expanding plasma collection networks and investing in fractionation and manufacturing facilities to secure the source-plasma supply and increase production capacity. Advances in plasma collection, fractionation, chromatography, and downstream purification are improving plasma utilization and the recovery of therapeutic proteins, including immunoglobulins, albumin, and coagulation factors. However, market growth remains constrained by high treatment costs and reimbursement constraints for plasma-derived products, particularly for long-term therapies requiring repeated administration. Differences in healthcare coverage, reimbursement policies, and patient affordability across countries can limit access to plasma-derived therapies, affecting adoption and creating challenges for market expansion while maintaining product quality, safety, and supply continuity.
The report’s scope encompasses detailed information on the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the plasma fractionation market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, product portfolios, key strategies, new product launches, acquisitions, and recent developments related to the plasma fractionation market. This report also includes a competitive analysis of emerging startups in the plasma fractionation industry ecosystem.
Immunoglobulins segment holds the largest share of the market
The immunoglobulins segment accounts for the largest share of the plasma fractionation market, driven by the increasing use of IVIG, SCIG, and other immunoglobulins to manage primary immunodeficiencies, autoimmune disorders, and neurological conditions. Immunoglobulins play a critical role in immunology and neurology, and recurring treatment needs support sustained demand for plasma-derived products. The growing prevalence of immune-mediated diseases, rising clinical adoption of immunoglobulin therapies, and continued investments in plasma collection and fractionation capacity are expected to further strengthen this segment's position.Therapeutics segment holds the largest share of the market
The therapeutics segment accounts for the largest share of the plasma fractionation market, driven by the widespread clinical use of plasma-derived medicinal products across immunology, neurology, hematology, critical care, and pulmonology. Therapeutic applications are critical to treating immunodeficiencies, autoimmune and neurological disorders, bleeding disorders, and other conditions requiring plasma-derived therapies. Growing demand for immunoglobulins, coagulation factor concentrates, albumin, and protease inhibitors, along with rising healthcare utilization and investments in plasma-derived product manufacturing, continues to strengthen this segment's position.US is expected to grow at the highest CAGR during the forecast period
The US is expected to post the highest CAGR in the plasma fractionation market, driven by a strong plasma collection infrastructure, an established presence of leading plasma fractionation companies, and high utilization of plasma-derived therapies. Rising demand for immunoglobulins, coagulation factor concentrates, albumin, and other plasma-derived products across therapeutic applications is supporting market growth. Growing investments in plasma collection capacity, fractionation and manufacturing facilities, and domestic supply capabilities are further strengthening the market. In addition, increasing adoption of advanced fractionation, purification, and high-concentration immunoglobulin formulations is expected to support demand across hospitals, specialty clinics, home care settings, and infusion centers.The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side - 70% and Demand Side- 30%
- By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives - 25%
- By Region: North America - 40%, Europe - 25%, Asia Pacific - 25%, Latin America - 5%, the Middle East & Africa - 5%
Research Coverage
This research report categorizes the plasma fractionation market by product (Immunoglobulins [IVIG, SCIG, and other Immunoglobulins], Coagulation factor concentrates [Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin complex concentrates, Factor XIII, and other coagulation factor concentrates], albumin, protease inhibitors, and other plasma products), application (therapeutics and academics & preclinical research), therapeutic area (neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications), end user (hospitals & specialty clinics, homecare settings & infusion centers, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa).The report’s scope encompasses detailed information on the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the plasma fractionation market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, product portfolios, key strategies, new product launches, acquisitions, and recent developments related to the plasma fractionation market. This report also includes a competitive analysis of emerging startups in the plasma fractionation industry ecosystem.
Key Benefits of Buying the Report
The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and provide information on key market drivers, restraints, opportunities, and challenges.The report provides insights into the following pointers:
- Analysis of key drivers (Growing demand for immunoglobulins across immunology and neurology, Strategic expansion of plasma collection capacity by market players, Growing prevalence of respiratory diseases and Alpha-1-antitrypsin deficiency, Increasing utilization of albumin in critical care), restraints (High treatment costs and reimbursement constraints for plasma-derived products, Market disruption caused by recombinant alternatives), opportunities (Government strategies for increasing regional self-sufficiency in plasma fractionation), and challenges (Stringent government regulations for maintaining safety and quality of plasma-derived products) influencing the market growth
- Product Development/Innovation: Detailed insights into newly launched products and innovations in the plasma fractionation market
- Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the plasma fractionation market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and products of leading players, CSL (Australia), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.p.A. (Italy), LFB (France), ADMA Biologics, Inc. (USA), Sanquin (Netherlands), Taibang Biological Group Co., Ltd. (China), GC Biopharma Corporate (South Korea), Hualan Bioengineering Inc. (China), Japan Blood Products Organization (Japan), Emergent (USA), Shanghai RAAS Blood Products Co., Ltd. (China), and Intas Pharmaceuticals Ltd. (India) among others, in the plasma fractionation market
Table of Contents
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN PLASMA FRACTIONATION MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN PLASMA FRACTIONATION MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 PLASMA FRACTIONATION MARKET OVERVIEW
3.2 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION
3.3 PLASMA FRACTIONATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.4 PLASMA FRACTIONATION MARKET SHARE, BY PRODUCT, 2026 VS. 2031 (%)
3.2 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION
3.3 PLASMA FRACTIONATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.4 PLASMA FRACTIONATION MARKET SHARE, BY PRODUCT, 2026 VS. 2031 (%)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Growing demand for immunoglobulins across immunologyand neurology
4.2.1.2 Strategic expansion of plasma collection capacity by market players
4.2.1.2.1 Plasma collection-by volume
4.2.1.2.1.1 US
4.2.1.2.1.2 Canada
4.2.1.2.1.3 United Kingdom
4.2.1.2.1.4 Japan
4.2.1.2.1.5 India
4.2.1.2.1.6 Brazil
4.2.1.3 Growing prevalence of respiratory diseases and alpha-
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Growing demand for immunoglobulins across immunologyand neurology
4.2.1.2 Strategic expansion of plasma collection capacity by market players
4.2.1.2.1 Plasma collection-by volume
4.2.1.2.1.1 US
4.2.1.2.1.2 Canada
4.2.1.2.1.3 United Kingdom
4.2.1.2.1.4 Japan
4.2.1.2.1.5 India
4.2.1.2.1.6 Brazil
4.2.1.3 Growing prevalence of respiratory diseases and alpha-
1 antitrypsin deficiency
4.2.1.4 Increasing utilization of albumin in critical care
4.2.2 RESTRAINTS
4.2.2.1 High treatment costs and reimbursement constraints for plasma-derived products
4.2.2.2 Market disruption caused by recombinant alternatives
4.2.3 OPPORTUNITIES
4.2.3.1 Government strategies for increasing regional self-sufficiency in plasma fractionation
4.2.4 CHALLENGES
4.2.4.1 Stringent government regulations for maintaining safety and quality of plasma-derived products
4.3 UNMET NEEDS & WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
4.2.2 RESTRAINTS
4.2.2.1 High treatment costs and reimbursement constraints for plasma-derived products
4.2.2.2 Market disruption caused by recombinant alternatives
4.2.3 OPPORTUNITIES
4.2.3.1 Government strategies for increasing regional self-sufficiency in plasma fractionation
4.2.4 CHALLENGES
4.2.4.1 Stringent government regulations for maintaining safety and quality of plasma-derived products
4.3 UNMET NEEDS & WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 INTENSITY OF COMPETITIVE RIVALRY
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 THREAT OF NEW ENTRANTS
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS & FORECAST
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4 TRENDS IN GLOBAL BIOPHARMA INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.4.1 ROLE OF PLAYERS IN ECOSYSTEM
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2023-2025
5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025
5.6 TRADE ANALYSIS
5.6.1 IMPORT SCENARIO (HS CODE 3002.12)
5.6.2 EXPORT SCENARIO (HS CODE 3002.12)
5.7 KEY CONFERENCES & EVENTS, 2026-2027
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 INVESTMENT & FUNDING SCENARIO
5.10 CASE STUDY ANALYSIS
5.10.1 UK APPROVES DOMESTIC PLASMA FOR FIVE ADDITIONAL PDMPS
5.10.2 TAKEDA'S INDONESIA COLLABORATION STRENGTHENS NATIONAL PDMP ECOSYSTEM
5.10.3 ADVANCED VIRAL INACTIVATION IMPROVES PLASMA-DERIVED PRODUCT MANUFACTURING
5.11 IMPACT OF 2025 US TARIFFS ON PLASMA FRACTIONATION MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON COUNTRY/REGION
5.11.4.1 US
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 IMPACT ON END-USE INDUSTRIES
5.11.5.1 Hospitals & specialty clinics
5.11.5.2 Homecare settings & infusion centers
5.11.5.3 Other end users
5.1.1 INTENSITY OF COMPETITIVE RIVALRY
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 THREAT OF NEW ENTRANTS
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS & FORECAST
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4 TRENDS IN GLOBAL BIOPHARMA INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.4.1 ROLE OF PLAYERS IN ECOSYSTEM
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2023-2025
5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025
5.6 TRADE ANALYSIS
5.6.1 IMPORT SCENARIO (HS CODE 3002.12)
5.6.2 EXPORT SCENARIO (HS CODE 3002.12)
5.7 KEY CONFERENCES & EVENTS, 2026-2027
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 INVESTMENT & FUNDING SCENARIO
5.10 CASE STUDY ANALYSIS
5.10.1 UK APPROVES DOMESTIC PLASMA FOR FIVE ADDITIONAL PDMPS
5.10.2 TAKEDA'S INDONESIA COLLABORATION STRENGTHENS NATIONAL PDMP ECOSYSTEM
5.10.3 ADVANCED VIRAL INACTIVATION IMPROVES PLASMA-DERIVED PRODUCT MANUFACTURING
5.11 IMPACT OF 2025 US TARIFFS ON PLASMA FRACTIONATION MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON COUNTRY/REGION
5.11.4.1 US
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 IMPACT ON END-USE INDUSTRIES
5.11.5.1 Hospitals & specialty clinics
5.11.5.2 Homecare settings & infusion centers
5.11.5.3 Other end users
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 TECHNOLOGY ANALYSIS
6.1.1 KEY TECHNOLOGIES
6.1.1.1 Cohn’s cold ethanol plasma fractionation
6.1.1.2 Plasma fractionation by chromatography
6.1.1.3 Plasma separation by centrifugation
6.1.1.4 Plasma separation by depth filtration
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 Facilitated subcutaneous infusion systems
6.1.2.2 Liquid-stable high-concentration (20%) formulations
6.1.2.3 Single-use bioprocessing & continuous chromatography
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 AI-driven analytics & smart fractionation yield optimization
6.1.3.2 Next-generation automated plasmapheresis & smart donor center systems
6.2 TECHNOLOGY ROADMAP
6.3 PATENT ANALYSIS
6.3.1 METHODOLOGY
6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
6.3.3 LIST OF KEY PATENTS
6.4 FUTURE APPLICATIONS
6.5 IMPACT OF AI/GEN AI ON PLASMA FRACTIONATION MARKET
6.5.1 TOP USE CASES & MARKET POTENTIAL
6.5.2 BEST PRACTICES IN AI-ENABLED PLASMA FRACTIONATION WORKFLOWS
6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN PLASMA FRACTIONATION MARKET
6.5.4 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
6.5.5 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED PLASMA FRACTIONATION TECHNOLOGIES
6.1.1 KEY TECHNOLOGIES
6.1.1.1 Cohn’s cold ethanol plasma fractionation
6.1.1.2 Plasma fractionation by chromatography
6.1.1.3 Plasma separation by centrifugation
6.1.1.4 Plasma separation by depth filtration
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 Facilitated subcutaneous infusion systems
6.1.2.2 Liquid-stable high-concentration (20%) formulations
6.1.2.3 Single-use bioprocessing & continuous chromatography
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 AI-driven analytics & smart fractionation yield optimization
6.1.3.2 Next-generation automated plasmapheresis & smart donor center systems
6.2 TECHNOLOGY ROADMAP
6.3 PATENT ANALYSIS
6.3.1 METHODOLOGY
6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
6.3.3 LIST OF KEY PATENTS
6.4 FUTURE APPLICATIONS
6.5 IMPACT OF AI/GEN AI ON PLASMA FRACTIONATION MARKET
6.5.1 TOP USE CASES & MARKET POTENTIAL
6.5.2 BEST PRACTICES IN AI-ENABLED PLASMA FRACTIONATION WORKFLOWS
6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN PLASMA FRACTIONATION MARKET
6.5.4 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
6.5.5 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED PLASMA FRACTIONATION TECHNOLOGIES
7 SUSTAINABILITY & REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS & COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
7.1.2.1 North America
7.1.2.2 Europe
7.1.2.3 Asia Pacific
7.1.2.4 Rest of the World
7.2 SUSTAINABILITY INITIATIVES
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
7.1.2.1 North America
7.1.2.2 Europe
7.1.2.3 Asia Pacific
7.1.2.4 Rest of the World
7.2 SUSTAINABILITY INITIATIVES
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA, BY END USER
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA, BY END USER
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9 PLASMA FRACTIONATION MARKET, BY PRODUCT
9.1 INTRODUCTION
9.2 IMMUNOGLOBULINS
9.2.1 IVIG
9.2.1.1 Expanding clinical indications, rising immune disorder diagnoses, and advances in IVIG formulations to drive market growth
9.2.2 SCIG
9.2.2.1 Rising preference for home-based treatment, expanding neurological indications, and patient-friendly administration to drive SCIG demand
9.2.3 OTHER IMMUNOGLOBULINS
9.3 COAGULATION FACTOR CONCENTRATES
9.3.1 FACTOR VIII
9.3.1.1 Improved hemophilia diagnosis and reliable plasma-derived product supply to boost demand for Factor VIII
9.3.2 FACTOR IX
9.3.2.1 Hemophilia B diagnosis and continued demand for replacement therapy to support Factor IX utilization
9.3.3 VON WILLEBRAND FACTOR
9.3.3.1 Expanded pediatric prophylaxis and increasing access to specialized bleeding disorder care to support market growth
9.3.4 PROTHROMBIN COMPLEX CONCENTRATES (PCC)
9.3.4.1 Rapid anticoagulation reversal and rising emergency-care requirements to aid market growth
9.3.5 FIBRINOGEN CONCENTRATES
9.3.5.1 Rising demand for targeted coagulation replacement to drive global market growth
9.3.6 FACTOR XIII
9.3.6.1 Growing demand for preventive replacement therapy to support market growth
9.3.7 OTHER COAGULATION FACTOR CONCENTRATES
9.4 ALBUMIN
9.4.1 RISING DEMAND FOR CRITICAL CARE AND LIVER DISEASE THERAPIES TO BOOST MARKET GROWTH
9.5 PROTEASE INHIBITORS
9.5.1 INCREASING AATD DIAGNOSIS AND DEMAND FOR LONG-TERM AUGMENTATION THERAPY TO PROPEL MARKET
9.6 OTHER PLASMA PRODUCTS
9.2 IMMUNOGLOBULINS
9.2.1 IVIG
9.2.1.1 Expanding clinical indications, rising immune disorder diagnoses, and advances in IVIG formulations to drive market growth
9.2.2 SCIG
9.2.2.1 Rising preference for home-based treatment, expanding neurological indications, and patient-friendly administration to drive SCIG demand
9.2.3 OTHER IMMUNOGLOBULINS
9.3 COAGULATION FACTOR CONCENTRATES
9.3.1 FACTOR VIII
9.3.1.1 Improved hemophilia diagnosis and reliable plasma-derived product supply to boost demand for Factor VIII
9.3.2 FACTOR IX
9.3.2.1 Hemophilia B diagnosis and continued demand for replacement therapy to support Factor IX utilization
9.3.3 VON WILLEBRAND FACTOR
9.3.3.1 Expanded pediatric prophylaxis and increasing access to specialized bleeding disorder care to support market growth
9.3.4 PROTHROMBIN COMPLEX CONCENTRATES (PCC)
9.3.4.1 Rapid anticoagulation reversal and rising emergency-care requirements to aid market growth
9.3.5 FIBRINOGEN CONCENTRATES
9.3.5.1 Rising demand for targeted coagulation replacement to drive global market growth
9.3.6 FACTOR XIII
9.3.6.1 Growing demand for preventive replacement therapy to support market growth
9.3.7 OTHER COAGULATION FACTOR CONCENTRATES
9.4 ALBUMIN
9.4.1 RISING DEMAND FOR CRITICAL CARE AND LIVER DISEASE THERAPIES TO BOOST MARKET GROWTH
9.5 PROTEASE INHIBITORS
9.5.1 INCREASING AATD DIAGNOSIS AND DEMAND FOR LONG-TERM AUGMENTATION THERAPY TO PROPEL MARKET
9.6 OTHER PLASMA PRODUCTS
10 PLASMA FRACTIONATION MARKET, BY APPLICATION
10.1 INTRODUCTION
10.2 THERAPEUTICS
10.2.1 STRONG CLINICAL DEMAND FOR PLASMA-DERIVED THERAPIES TO SUSTAIN THERAPEUTICS AS CORE APPLICATION OF PLASMA FRACTIONATION MARKET
10.3 ACADEMICS & PRECLINICAL RESEARCH
10.3.1 EXPANDING USE OF HUMAN PLASMA FRACTIONS IN RESEARCH AND BIOPROCESSING TO SUPPORT DEMAND
10.2 THERAPEUTICS
10.2.1 STRONG CLINICAL DEMAND FOR PLASMA-DERIVED THERAPIES TO SUSTAIN THERAPEUTICS AS CORE APPLICATION OF PLASMA FRACTIONATION MARKET
10.3 ACADEMICS & PRECLINICAL RESEARCH
10.3.1 EXPANDING USE OF HUMAN PLASMA FRACTIONS IN RESEARCH AND BIOPROCESSING TO SUPPORT DEMAND
11 PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA
11.1 INTRODUCTION
11.2 NEUROLOGY
11.2.1 GROWING UTILIZATION OF PLASMA-DERIVED IMMUNOGLOBULINS IN NEUROLOGICAL DISORDERS TO DRIVE DEMAND FOR PLASMA FRACTIONATION
11.3 IMMUNOLOGY
11.3.1 INCREASING PREVALENCE OF IMMUNODEFICIENCIES AND AUTOIMMUNE DISORDERS TO DRIVE DEMAND FOR PLASMA-DERIVED IMMUNOGLOBULINS
11.4 HEMATOLOGY
11.4.1 RISING DEMAND FOR PLASMA-DERIVED COAGULATION FACTORS TO SUPPORT TREATMENT OF BLEEDING DISORDERS
11.5 CRITICAL CARE
11.5.1 ESSENTIAL DEMAND FOR ALBUMIN EXPANDERS AND FOUR-FACTOR CONCENTRATE REVERSAL AGENTS TO DRIVE CLINICAL UTILITY IN EMERGENCY SETTINGS
11.6 PULMONOLOGY
11.6.1 GROWING DIAGNOSIS OF ALPHA-1 ANTITRYPSIN DEFICIENCY TO SUPPORT DEMAND FOR PLASMA-DERIVED PROTEASE INHIBITORS
11.7 HEMATO-ONCOLOGY
11.7.1 INCREASING SUPPORTIVE-CARE REQUIREMENTS IN HEMATOLOGICAL MALIGNANCIES TO SUPPORT UTILIZATION OF PLASMA-DERIVED PRODUCTS
11.8 RHEUMATOLOGY
11.8.1 EXPANDING USE OF IMMUNOGLOBULIN THERAPY IN IMMUNE-MEDIATED DISORDERS TO SUPPORT DEMAND FOR PLASMA-DERIVED PRODUCTS
11.9 OTHER THERAPEUTIC AREAS
11.2 NEUROLOGY
11.2.1 GROWING UTILIZATION OF PLASMA-DERIVED IMMUNOGLOBULINS IN NEUROLOGICAL DISORDERS TO DRIVE DEMAND FOR PLASMA FRACTIONATION
11.3 IMMUNOLOGY
11.3.1 INCREASING PREVALENCE OF IMMUNODEFICIENCIES AND AUTOIMMUNE DISORDERS TO DRIVE DEMAND FOR PLASMA-DERIVED IMMUNOGLOBULINS
11.4 HEMATOLOGY
11.4.1 RISING DEMAND FOR PLASMA-DERIVED COAGULATION FACTORS TO SUPPORT TREATMENT OF BLEEDING DISORDERS
11.5 CRITICAL CARE
11.5.1 ESSENTIAL DEMAND FOR ALBUMIN EXPANDERS AND FOUR-FACTOR CONCENTRATE REVERSAL AGENTS TO DRIVE CLINICAL UTILITY IN EMERGENCY SETTINGS
11.6 PULMONOLOGY
11.6.1 GROWING DIAGNOSIS OF ALPHA-1 ANTITRYPSIN DEFICIENCY TO SUPPORT DEMAND FOR PLASMA-DERIVED PROTEASE INHIBITORS
11.7 HEMATO-ONCOLOGY
11.7.1 INCREASING SUPPORTIVE-CARE REQUIREMENTS IN HEMATOLOGICAL MALIGNANCIES TO SUPPORT UTILIZATION OF PLASMA-DERIVED PRODUCTS
11.8 RHEUMATOLOGY
11.8.1 EXPANDING USE OF IMMUNOGLOBULIN THERAPY IN IMMUNE-MEDIATED DISORDERS TO SUPPORT DEMAND FOR PLASMA-DERIVED PRODUCTS
11.9 OTHER THERAPEUTIC AREAS
12 PLASMA FRACTIONATION MARKET, BY END USER
12.1 INTRODUCTION
12.2 HOSPITALS & SPECIALTY CLINICS
12.2.1 INCREASING UTILIZATION OF PLASMA-DERIVED THERAPIES ACROSS CLINICAL TREATMENT SETTINGS TO DRIVE DEMAND FOR PLASMA FRACTIONATION PRODUCTS
12.3 HOME CARE SETTINGS & INFUSION CENTERS
12.3.1 GROWING ADOPTION OF HOME-BASED IMMUNOGLOBULIN ADMINISTRATION TO SUPPORT DEMAND FOR PLASMA-DERIVED THERAPIES
12.4 OTHER END USERS
12.2 HOSPITALS & SPECIALTY CLINICS
12.2.1 INCREASING UTILIZATION OF PLASMA-DERIVED THERAPIES ACROSS CLINICAL TREATMENT SETTINGS TO DRIVE DEMAND FOR PLASMA FRACTIONATION PRODUCTS
12.3 HOME CARE SETTINGS & INFUSION CENTERS
12.3.1 GROWING ADOPTION OF HOME-BASED IMMUNOGLOBULIN ADMINISTRATION TO SUPPORT DEMAND FOR PLASMA-DERIVED THERAPIES
12.4 OTHER END USERS
13 PLASMA FRACTIONATION MARKET, BY REGION
13.1 INTRODUCTION
13.2 NORTH AMERICA
13.2.1 US
13.2.1.1 Expanding plasma collection, fractionation capacity, and immunoglobulin demand to drive US market growth
13.2.2 CANADA
13.2.2.1 Rising immunoglobulin demand and investments in domestic plasma supply to drive market growth
13.3 EUROPE
13.3.1 GERMANY
13.3.1.1 Expanding plasma collection infrastructure and rising demand for plasma-derived therapies to drive market growth in Germany
13.3.2 UK
13.3.2.1 Rising immunoglobulin demand, domestic plasma collection, and investments in fractionation capacity to boost market growth
13.3.3 FRANCE
13.3.3.1 Established healthcare infrastructure and public plasma donation model to support access to treatment
13.3.4 ITALY
13.3.4.1 Growing use of immunoglobulins for neurological and immunological disorders to drive demand
13.3.5 SPAIN
13.3.5.1 Growing utilization of albumin for critical care and coagulation factor concentrates for bleeding disorders to support growth
13.3.6 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 CHINA
13.4.1.1 Large domestic donor-plasma collection network and manufacturers focused on expanding product availability to drive growth
13.4.2 JAPAN
13.4.2.1 Highly organized blood donation system and national focus on securing plasma for domestic therapeutic requirements to boost market
13.4.3 INDIA
13.4.3.1 Substantial unmet treatment needs and efforts to improve access to quality-assured plasma-derived medicines to drive growth
13.4.4 SOUTH KOREA
13.4.4.1 Domestic manufacturing expertise with investments in storage infrastructure and overseas contract manufacturing to expand market
13.4.5 AUSTRALIA
13.4.5.1 National self-sufficiency policy linking locally collected plasma with domestic manufacturing and patient supply to position Australia as major hub
13.4.6 VIETNAM
13.4.6.1 Improvements in healthcare access and growing awareness of plasma-derived therapies to support demand
13.4.7 MALAYSIA
13.4.7.1 Dependence on imported plasma-derived therapies to increase focus on plasma collection, contract fractionation, and long-term supply agreements
13.4.8 INDONESIA
13.4.8.1 Large patient population and increasing diagnosis of neurological and immunological disorders to support demand for immunoglobulins
13.4.9 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
13.5.1 BRAZIL
13.5.1.1 Expanding local processing to create opportunities to improve plasma utilization and strengthen Brazil's biopharmaceutical supply chain
13.5.2 MEXICO
13.5.2.1 Broader national strategy to expand pharmaceutical manufacturing and reduce reliance on imported medicines to drive market
13.5.3 REST OF LATIN AMERICA
13.6 MIDDLE EAST
13.6.1 GCC COUNTRIES
13.6.1.1 Saudi Arabia
13.6.1.1.1 National objective of achieving self-sufficiency in plasma-derived medicines and reducing dependence on imported therapies to aid growth
13.6.1.2 UAE
13.6.1.2.1 Growing investment in pharmaceutical localization and efforts to strengthen national medicine security to boost growth
13.6.1.3 Rest of GCC Countries
13.6.2 TURKEY
13.6.2.1 Domestic fractionation investment, import substitution, and rising demand for plasma-derived therapies to drive growth
13.6.3 EGYPT
13.6.3.1 Domestic plasma self-sufficiency, expanding collection infrastructure, and investment in local fractionation to fuel market
13.6.4 REST OF MIDDLE EAST
13.7 AFRICA
13.7.1 INVESTMENTS IN PLASMA COLLECTION, DOMESTIC MANUFACTURING, AND INTERNATIONAL PARTNERSHIPS TO SUPPORT DEVELOPMENT OF MARKET
13.2 NORTH AMERICA
13.2.1 US
13.2.1.1 Expanding plasma collection, fractionation capacity, and immunoglobulin demand to drive US market growth
13.2.2 CANADA
13.2.2.1 Rising immunoglobulin demand and investments in domestic plasma supply to drive market growth
13.3 EUROPE
13.3.1 GERMANY
13.3.1.1 Expanding plasma collection infrastructure and rising demand for plasma-derived therapies to drive market growth in Germany
13.3.2 UK
13.3.2.1 Rising immunoglobulin demand, domestic plasma collection, and investments in fractionation capacity to boost market growth
13.3.3 FRANCE
13.3.3.1 Established healthcare infrastructure and public plasma donation model to support access to treatment
13.3.4 ITALY
13.3.4.1 Growing use of immunoglobulins for neurological and immunological disorders to drive demand
13.3.5 SPAIN
13.3.5.1 Growing utilization of albumin for critical care and coagulation factor concentrates for bleeding disorders to support growth
13.3.6 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 CHINA
13.4.1.1 Large domestic donor-plasma collection network and manufacturers focused on expanding product availability to drive growth
13.4.2 JAPAN
13.4.2.1 Highly organized blood donation system and national focus on securing plasma for domestic therapeutic requirements to boost market
13.4.3 INDIA
13.4.3.1 Substantial unmet treatment needs and efforts to improve access to quality-assured plasma-derived medicines to drive growth
13.4.4 SOUTH KOREA
13.4.4.1 Domestic manufacturing expertise with investments in storage infrastructure and overseas contract manufacturing to expand market
13.4.5 AUSTRALIA
13.4.5.1 National self-sufficiency policy linking locally collected plasma with domestic manufacturing and patient supply to position Australia as major hub
13.4.6 VIETNAM
13.4.6.1 Improvements in healthcare access and growing awareness of plasma-derived therapies to support demand
13.4.7 MALAYSIA
13.4.7.1 Dependence on imported plasma-derived therapies to increase focus on plasma collection, contract fractionation, and long-term supply agreements
13.4.8 INDONESIA
13.4.8.1 Large patient population and increasing diagnosis of neurological and immunological disorders to support demand for immunoglobulins
13.4.9 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
13.5.1 BRAZIL
13.5.1.1 Expanding local processing to create opportunities to improve plasma utilization and strengthen Brazil's biopharmaceutical supply chain
13.5.2 MEXICO
13.5.2.1 Broader national strategy to expand pharmaceutical manufacturing and reduce reliance on imported medicines to drive market
13.5.3 REST OF LATIN AMERICA
13.6 MIDDLE EAST
13.6.1 GCC COUNTRIES
13.6.1.1 Saudi Arabia
13.6.1.1.1 National objective of achieving self-sufficiency in plasma-derived medicines and reducing dependence on imported therapies to aid growth
13.6.1.2 UAE
13.6.1.2.1 Growing investment in pharmaceutical localization and efforts to strengthen national medicine security to boost growth
13.6.1.3 Rest of GCC Countries
13.6.2 TURKEY
13.6.2.1 Domestic fractionation investment, import substitution, and rising demand for plasma-derived therapies to drive growth
13.6.3 EGYPT
13.6.3.1 Domestic plasma self-sufficiency, expanding collection infrastructure, and investment in local fractionation to fuel market
13.6.4 REST OF MIDDLE EAST
13.7 AFRICA
13.7.1 INVESTMENTS IN PLASMA COLLECTION, DOMESTIC MANUFACTURING, AND INTERNATIONAL PARTNERSHIPS TO SUPPORT DEVELOPMENT OF MARKET
14 COMPETITIVE LANDSCAPE
14.1 OVERVIEW
14.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023-2026
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PLASMA FRACTIONATION MARKET, JANUARY 2023-AUGUST 2026
14.3 REVENUE ANALYSIS, 2021-2025
14.4 MARKET SHARE ANALYSIS, 2025
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
14.5.1 STARS
14.5.2 EMERGING LEADERS
14.5.3 PERVASIVE PLAYERS
14.5.4 PARTICIPANTS
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
14.5.5.1 Company footprint
14.5.5.2 Region footprint
14.5.5.3 Product footprint
14.5.5.4 Therapeutic area footprint
14.5.5.5 Application footprint
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
14.6.1 PROGRESSIVE COMPANIES
14.6.2 RESPONSIVE COMPANIES
14.6.3 DYNAMIC COMPANIES
14.6.4 STARTING BLOCKS
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
14.6.5.1 Detailed list of key startup/SME players
14.6.5.2 Competitive benchmarking of startups/SMEs
14.7 COMPANY VALUATION & FINANCIAL METRICS
14.7.1 COMPANY VALUATION
14.7.2 COMPANY VALUATION
14.8 BRAND/PRODUCT COMPARISON
14.9 COMPETITIVE SCENARIO
14.9.1 PRODUCT LAUNCHES
14.9.2 DEALS
14.9.3 EXPANSIONS
14.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023-2026
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PLASMA FRACTIONATION MARKET, JANUARY 2023-AUGUST 2026
14.3 REVENUE ANALYSIS, 2021-2025
14.4 MARKET SHARE ANALYSIS, 2025
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
14.5.1 STARS
14.5.2 EMERGING LEADERS
14.5.3 PERVASIVE PLAYERS
14.5.4 PARTICIPANTS
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
14.5.5.1 Company footprint
14.5.5.2 Region footprint
14.5.5.3 Product footprint
14.5.5.4 Therapeutic area footprint
14.5.5.5 Application footprint
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
14.6.1 PROGRESSIVE COMPANIES
14.6.2 RESPONSIVE COMPANIES
14.6.3 DYNAMIC COMPANIES
14.6.4 STARTING BLOCKS
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
14.6.5.1 Detailed list of key startup/SME players
14.6.5.2 Competitive benchmarking of startups/SMEs
14.7 COMPANY VALUATION & FINANCIAL METRICS
14.7.1 COMPANY VALUATION
14.7.2 COMPANY VALUATION
14.8 BRAND/PRODUCT COMPARISON
14.9 COMPETITIVE SCENARIO
14.9.1 PRODUCT LAUNCHES
14.9.2 DEALS
14.9.3 EXPANSIONS
15 COMPANY PROFILES
15.1 KEY PLAYERS
15.1.1 CSL
15.1.1.1 Business overview
15.1.1.2 Products offered
15.1.1.3 Recent developments
15.1.1.3.1 Product launches
15.1.1.3.2 Expansions
15.1.1.4 Analyst's view
15.1.1.4.1 Key strengths
15.1.1.4.2 Strategic choices
15.1.1.4.3 Weaknesses & competitive threats
15.1.2 GRIFOLS, S.A.
15.1.2.1 Business overview
15.1.2.2 Products offered
15.1.2.3 Recent developments
15.1.2.3.1 Product launches
15.1.2.3.2 Deals
15.1.2.3.3 Expansions
15.1.2.4 Analyst's view
15.1.2.4.1 Key strengths
15.1.2.4.2 Strategic choices
15.1.2.4.3 Weaknesses & competitive threats
15.1.3 TAKEDA PHARMACEUTICAL COMPANY LIMITED
15.1.3.1 Business overview
15.1.3.2 Products offered
15.1.3.3 Recent developments
15.1.3.3.1 Product launches
15.1.3.3.2 Deals
15.1.3.3.3 Expansions
15.1.3.4 Analyst's view
15.1.3.4.1 Key strengths
15.1.3.4.2 Strategic choices
15.1.3.4.3 Weaknesses & competitive threats
15.1.4 OCTAPHARMA AG
15.1.4.1 Business overview
15.1.4.2 Products offered
15.1.4.3 Recent developments
15.1.4.3.1 Product launches
15.1.4.3.2 Expansions
15.1.4.4 Analyst's view
15.1.4.4.1 Key strengths
15.1.4.4.2 Strategic choices
15.1.4.4.3 Weaknesses & competitive threats
15.1.5 KEDRION S.P.A.
15.1.5.1 Business overview
15.1.5.2 Products offered
15.1.5.3 Recent developments
15.1.5.3.1 Product launches
15.1.5.3.2 Deals
15.1.5.3.3 Expansions
15.1.5.4 Analyst's view
15.1.5.4.1 Key strengths
15.1.5.4.2 Strategic choices
15.1.5.4.3 Weaknesses & competitive threats
15.1.6 LFB
15.1.6.1 Business overview
15.1.6.2 Products offered
15.1.6.3 Recent developments
15.1.6.3.1 Expansions
15.1.7 ADMA BIOLOGICS, INC.
15.1.7.1 Business overview
15.1.7.2 Products offered
15.1.7.3 Recent developments
15.1.7.3.1 Deals
15.1.8 SANQUIN
15.1.8.1 Business overview
15.1.8.2 Products offered
15.1.8.3 Recent developments
15.1.8.3.1 Expansions
15.1.9 TAIBANG BIOLOGICAL GROUP CO., LTD.
15.1.9.1 Business overview
15.1.9.2 Products offered
15.1.9.3 Recent developments
15.1.9.3.1 Expansions
15.1.10 GC BIOPHARMA CORPORATE
15.1.10.1 Business overview
15.1.10.2 Products offered
15.1.10.3 Recent developments
15.1.10.3.1 Product launches
15.1.10.3.2 Deals
15.1.10.3.3 Expansions
15.1.11 HUALAN BIOLOGICAL ENGINEERING INC.
15.1.11.1 Business overview
15.1.11.2 Products offered
15.1.12 JAPAN BLOOD PRODUCTS ORGANIZATION
15.1.12.1 Business overview
15.1.12.2 Products offered
15.1.12.3 Recent developments
15.1.12.3.1 Product launches
15.1.12.3.2 Expansions
15.1.13 EMERGENT
15.1.13.1 Business overview
15.1.13.2 Products offered
15.1.14 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.
15.1.14.1 Business overview
15.1.14.2 Products offered
15.1.14.3 Recent developments
15.1.14.3.1 Deals
15.1.15 INTAS PHARMACEUTICALS LTD.
15.1.15.1 Business overview
15.1.15.2 Products offered
15.1.15.3 Recent developments
15.1.15.3.1 Deals
15.1.15.3.2 Expansions
15.2 OTHER PLAYERS
15.2.1 BHARAT SERUMS AND VACCINES LIMITED
15.2.2 SK PLASMA
15.2.3 SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO., LTD.
15.2.4 KAMADA PHARMACEUTICALS
15.2.5 CENTURION
15.2.6 PLASMAGEN BIOSCIENCES PVT. LTD.
15.2.7 VIRCHOW BIOTECH
15.2.8 FUSION HEALTHCARE
15.2.9 ICHOR
15.1.1 CSL
15.1.1.1 Business overview
15.1.1.2 Products offered
15.1.1.3 Recent developments
15.1.1.3.1 Product launches
15.1.1.3.2 Expansions
15.1.1.4 Analyst's view
15.1.1.4.1 Key strengths
15.1.1.4.2 Strategic choices
15.1.1.4.3 Weaknesses & competitive threats
15.1.2 GRIFOLS, S.A.
15.1.2.1 Business overview
15.1.2.2 Products offered
15.1.2.3 Recent developments
15.1.2.3.1 Product launches
15.1.2.3.2 Deals
15.1.2.3.3 Expansions
15.1.2.4 Analyst's view
15.1.2.4.1 Key strengths
15.1.2.4.2 Strategic choices
15.1.2.4.3 Weaknesses & competitive threats
15.1.3 TAKEDA PHARMACEUTICAL COMPANY LIMITED
15.1.3.1 Business overview
15.1.3.2 Products offered
15.1.3.3 Recent developments
15.1.3.3.1 Product launches
15.1.3.3.2 Deals
15.1.3.3.3 Expansions
15.1.3.4 Analyst's view
15.1.3.4.1 Key strengths
15.1.3.4.2 Strategic choices
15.1.3.4.3 Weaknesses & competitive threats
15.1.4 OCTAPHARMA AG
15.1.4.1 Business overview
15.1.4.2 Products offered
15.1.4.3 Recent developments
15.1.4.3.1 Product launches
15.1.4.3.2 Expansions
15.1.4.4 Analyst's view
15.1.4.4.1 Key strengths
15.1.4.4.2 Strategic choices
15.1.4.4.3 Weaknesses & competitive threats
15.1.5 KEDRION S.P.A.
15.1.5.1 Business overview
15.1.5.2 Products offered
15.1.5.3 Recent developments
15.1.5.3.1 Product launches
15.1.5.3.2 Deals
15.1.5.3.3 Expansions
15.1.5.4 Analyst's view
15.1.5.4.1 Key strengths
15.1.5.4.2 Strategic choices
15.1.5.4.3 Weaknesses & competitive threats
15.1.6 LFB
15.1.6.1 Business overview
15.1.6.2 Products offered
15.1.6.3 Recent developments
15.1.6.3.1 Expansions
15.1.7 ADMA BIOLOGICS, INC.
15.1.7.1 Business overview
15.1.7.2 Products offered
15.1.7.3 Recent developments
15.1.7.3.1 Deals
15.1.8 SANQUIN
15.1.8.1 Business overview
15.1.8.2 Products offered
15.1.8.3 Recent developments
15.1.8.3.1 Expansions
15.1.9 TAIBANG BIOLOGICAL GROUP CO., LTD.
15.1.9.1 Business overview
15.1.9.2 Products offered
15.1.9.3 Recent developments
15.1.9.3.1 Expansions
15.1.10 GC BIOPHARMA CORPORATE
15.1.10.1 Business overview
15.1.10.2 Products offered
15.1.10.3 Recent developments
15.1.10.3.1 Product launches
15.1.10.3.2 Deals
15.1.10.3.3 Expansions
15.1.11 HUALAN BIOLOGICAL ENGINEERING INC.
15.1.11.1 Business overview
15.1.11.2 Products offered
15.1.12 JAPAN BLOOD PRODUCTS ORGANIZATION
15.1.12.1 Business overview
15.1.12.2 Products offered
15.1.12.3 Recent developments
15.1.12.3.1 Product launches
15.1.12.3.2 Expansions
15.1.13 EMERGENT
15.1.13.1 Business overview
15.1.13.2 Products offered
15.1.14 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.
15.1.14.1 Business overview
15.1.14.2 Products offered
15.1.14.3 Recent developments
15.1.14.3.1 Deals
15.1.15 INTAS PHARMACEUTICALS LTD.
15.1.15.1 Business overview
15.1.15.2 Products offered
15.1.15.3 Recent developments
15.1.15.3.1 Deals
15.1.15.3.2 Expansions
15.2 OTHER PLAYERS
15.2.1 BHARAT SERUMS AND VACCINES LIMITED
15.2.2 SK PLASMA
15.2.3 SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO., LTD.
15.2.4 KAMADA PHARMACEUTICALS
15.2.5 CENTURION
15.2.6 PLASMAGEN BIOSCIENCES PVT. LTD.
15.2.7 VIRCHOW BIOTECH
15.2.8 FUSION HEALTHCARE
15.2.9 ICHOR
16 RESEARCH METHODOLOGY
16.1 RESEARCH DATA
16.1.1 SECONDARY DATA
16.1.1.1 Key data from secondary sources
16.1.2 PRIMARY DATA
16.1.2.1 Key data from primary sources
16.1.2.2 Key primary participants
16.1.2.3 Breakdown of primary interviews
16.1.2.4 Key industry insights
16.2 MARKET SIZE ESTIMATION
16.2.1 GLOBAL PLASMA FRACTIONATION MARKET ESTIMATION, 2025
16.2.2 SEGMENTAL MARKET SIZE ESTIMATION
16.3 MARKET GROWTH RATE PROJECTIONS
16.4 DATA TRIANGULATION
16.5 FACTOR ANALYSIS
16.6 RESEARCH ASSUMPTIONS
16.7 RESEARCH LIMITATIONS & RISK ASSESSMENT
16.1.1 SECONDARY DATA
16.1.1.1 Key data from secondary sources
16.1.2 PRIMARY DATA
16.1.2.1 Key data from primary sources
16.1.2.2 Key primary participants
16.1.2.3 Breakdown of primary interviews
16.1.2.4 Key industry insights
16.2 MARKET SIZE ESTIMATION
16.2.1 GLOBAL PLASMA FRACTIONATION MARKET ESTIMATION, 2025
16.2.2 SEGMENTAL MARKET SIZE ESTIMATION
16.3 MARKET GROWTH RATE PROJECTIONS
16.4 DATA TRIANGULATION
16.5 FACTOR ANALYSIS
16.6 RESEARCH ASSUMPTIONS
16.7 RESEARCH LIMITATIONS & RISK ASSESSMENT
17 APPENDIX
17.1 DISCUSSION GUIDE
17.2 KNOWLEDGESTORE: THE SUBSCRIPTION PORTAL
17.3 CUSTOMIZATION OPTIONS
17.4 RELATED REPORTS
17.5 AUTHOR DETAILS
17.2 KNOWLEDGESTORE: THE SUBSCRIPTION PORTAL
17.3 CUSTOMIZATION OPTIONS
17.4 RELATED REPORTS
17.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 PLASMA FRACTIONATION MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 PLASMA FRACTIONATION MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 3 NUMBER OF PLASMA COLLECTION CENTERS, BY COMPANY, 2021-2022
TABLE 4 PLASMA FRACTIONATION MARKET: PORTER’S FIVE FORCES
TABLE 5 PLASMA FRACTIONATION MARKET: ROLE OF PLAYERS IN ECOSYSTEM
TABLE 6 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2023-2025 (USD)
TABLE 7 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025 (USD)
TABLE 8 IMPORT DATA FOR HS CODE 3002.12-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
TABLE 9 EXPORT DATA FOR HS CODE 3002.12-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
TABLE 10 PLASMA FRACTIONATION MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026-MARCH 2027
TABLE 11 RECIPROCAL TARIFF RATES ADJUSTED BY US
TABLE 12 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES
TABLE 13 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2015-2025
TABLE 14 LIST OF KEY PATENTS IN PLASMA FRACTIONATION MARKET, 2023-2025
TABLE 15 CASE STUDIES OF AI IMPLEMENTATION IN PLASMA FRACTIONATION MARKET
TABLE 16 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED PLASMA FRACTIONATION TECHNOLOGIES IN PLASMA FRACTIONATION MARKET
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
TABLE 22 KEY BUYING CRITERIA, BY END USER
TABLE 23 PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 24 PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE,2024-2031 (USD MILLION)
TABLE 25 PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY REGION,2024-2031 (USD MILLION)
TABLE 26 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 27 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 28 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 29 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 30 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 31 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 32 PLASMA FRACTIONATION MARKET FOR IVIG, BY REGION,2024-2031 (USD MILLION)
TABLE 33 PLASMA FRACTIONATION MARKET FOR IVIG, 2024-2031 (METRIC TONS)
TABLE 34 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 35 EUROPE: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 36 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 37 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 38 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 39 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 40 PLASMA FRACTIONATION MARKET FOR SCIG, BY REGION,2024-2031 (USD MILLION)
TABLE 41 PLASMA FRACTIONATION MARKET FOR SCIG, 2024-2031 (METRIC TONS)
TABLE 42 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 43 EUROPE: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 44 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 45 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 46 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 47 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 48 PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY REGION, 2024-2031 (USD MILLION)
TABLE 49 PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS,2024-2031 (METRIC TONS)
TABLE 50 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 51 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 52 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 53 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 54 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 55 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 56 PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 57 PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY REGION, 2024-2031 (USD MILLION)
TABLE 58 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 59 EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 60 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 61 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 62 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 63 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 64 PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY REGION,2024-2031 (USD MILLION)
TABLE 65 PLASMA FRACTIONATION MARKET FOR FACTOR VIII, 2024-2031 (MILLION IU)
TABLE 66 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR VIII,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 67 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 68 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 69 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 70 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 71 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FACTOR VIII,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 72 PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY REGION,2024-2031 (USD MILLION)
TABLE 73 PLASMA FRACTIONATION MARKET FOR FACTOR IX, 2024-2031 (MILLION IU)
TABLE 74 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 75 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 76 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 77 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 78 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 79 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 80 PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY REGION, 2024-2031 (USD MILLION)
TABLE 81 PLASMA FRACTIONATION MARKET FOR FACTOR VON WILLEBRAND FACTOR,2024-2031 (MILLION LITER)
TABLE 82 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 83 EUROPE: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 84 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 85 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 86 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 87 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 88 PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY REGION, 2024-2031 (USD MILLION)
TABLE 89 PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, 2024-2031 (MILLION IU)
TABLE 90 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 91 EUROPE: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 92 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 93 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 94 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 95 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 96 PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY REGION, 2024-2031 (USD MILLION)
TABLE 97 PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES,2024-2031 (MILLION IU)
TABLE 98 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 99 EUROPE: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 100 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 101 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 102 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 103 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 104 PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY REGION,2024-2031 (USD MILLION)
TABLE 105 PLASMA FRACTIONATION MARKET FOR FACTOR XIII, 2024-2031 (MILLION IU)
TABLE 106 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XIII,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 107 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 108 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 109 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 110 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 111 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FACTOR XIII,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 112 PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY REGION, 2024-2031 (USD MILLION)
TABLE 113 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 114 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 115 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 116 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 117 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 118 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 119 PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY REGION,2024-2031 (USD MILLION)
TABLE 120 PLASMA FRACTIONATION MARKET FOR ALBUMIN, 2024-2031 (METRIC TONS)
TABLE 121 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 122 EUROPE: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 123 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 124 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 125 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 126 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 127 PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY REGION,2024-2031 (USD MILLION)
TABLE 128 PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS,2024-2031 (MILLION IU)
TABLE 129 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 130 EUROPE: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 131 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 132 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 133 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 134 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 135 PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY REGION, 2024-2031 (USD MILLION)
TABLE 136 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 137 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 138 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 139 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 140 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 141 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 142 PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 143 PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY REGION,2024-2031 (USD MILLION)
TABLE 144 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 145 EUROPE: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 146 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 147 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 148 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 149 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 150 PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH,BY REGION, 2024-2031 (USD MILLION)
TABLE 151 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 152 EUROPE: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 153 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 154 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 155 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 156 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 157 PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 158 PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY REGION,2024-2031 (USD MILLION)
TABLE 159 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 160 EUROPE: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 161 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 162 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 163 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 164 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR NEUROLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 165 PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY REGION,2024-2031 (USD MILLION)
TABLE 166 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 167 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 168 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 169 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 170 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 171 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 172 PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY REGION,2024-2031 (USD MILLION)
TABLE 173 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 174 EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 175 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 176 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 177 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 178 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 179 PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY REGION,2024-2031 (USD MILLION)
TABLE 180 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 181 EUROPE: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 182 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 183 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 184 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 185 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 186 PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY REGION,2024-2031 (USD MILLION)
TABLE 187 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 188 EUROPE: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 189 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 190 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 191 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 192 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 193 PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY REGION,2024-2031 (USD MILLION)
TABLE 194 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 195 EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 196 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 197 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 198 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 199 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 200 PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY REGION,2024-2031 (USD MILLION)
TABLE 201 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 202 EUROPE: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 203 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 204 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 205 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 206 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 207 PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024-2031 (USD MILLION)
TABLE 208 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 209 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 210 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 211 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 212 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 213 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 214 PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 215 PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS,BY REGION, 2024-2031 (USD MILLION)
TABLE 216 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 217 EUROPE: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 218 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 219 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 220 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 221 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 222 PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 223 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 224 EUROPE: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 225 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 226 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 227 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 228 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 229 PLASMA FRACTIONATION MARKET FOR OTHER END USERS, BY REGION,2024-2031 (USD MILLION)
TABLE 230 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER END USERS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 231 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER END USERS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 232 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER END USERS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 233 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER END USERS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 234 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER END USERS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 235 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER END USERS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 236 PLASMA FRACTIONATION MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 237 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 238 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 239 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY TYPE, 2024-2031 (USD MILLION)
TABLE 240 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 241 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 242 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
TABLE 243 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 244 US: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 245 US: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE,2024-2031 (USD MILLION)
TABLE 246 US: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 247 US: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 248 US: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 249 US: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 250 CANADA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 251 CANADA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 252 CANADA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 253 CANADA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 254 CANADA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 255 CANADA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 256 EUROPE: PLASMA FRACTIONATION MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 257 EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 258 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 259 EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 260 EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 261 EUROPE: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 262 EUROPE: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 263 GERMANY: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 264 GERMANY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 265 GERMANY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 266 GERMANY: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 267 GERMANY: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 268 GERMANY: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 269 UK: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 270 UK: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE,2024-2031 (USD MILLION)
TABLE 271 UK: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 272 UK: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 273 UK: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 274 UK: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 275 FRANCE: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 276 FRANCE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 277 FRANCE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 278 FRANCE: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 279 FRANCE: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 280 FRANCE: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 281 ITALY: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 282 ITALY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 283 ITALY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 284 ITALY: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 285 ITALY: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 286 ITALY: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 287 SPAIN: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 288 SPAIN: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 289 SPAIN: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 290 SPAIN: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 291 SPAIN: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 292 SPAIN: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 293 REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 294 REST OF EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY TYPE, 2024-2031 (USD MILLION)
TABLE 295 REST OF EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 296 REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 297 REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
TABLE 298 REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 299 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 300 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 301 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY TYPE, 2024-2031 (USD MILLION)
TABLE 302 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 303 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 304 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 305 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 306 CHINA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 307 CHINA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 308 CHINA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 309 CHINA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 310 CHINA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 311 CHINA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 312 JAPAN: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 313 JAPAN: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 314 JAPAN: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 315 JAPAN: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 316 JAPAN: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 317 JAPAN: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 318 INDIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 319 INDIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 320 INDIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 321 INDIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 322 INDIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 323 INDIA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 324 SOUTH KOREA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 325 SOUTH KOREA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY TYPE, 2024-2031 (USD MILLION)
TABLE 326 SOUTH KOREA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 327 SOUTH KOREA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 328 SOUTH KOREA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 329 SOUTH KOREA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 330 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 331 AUSTRALIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 332 AUSTRALIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 333 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 334 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 335 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 336 VIETNAM: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 337 VIETNAM: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 338 VIETNAM: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 339 VIETNAM: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 340 VIETNAM: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 341 VIETNAM: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 342 MALAYSIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 343 MALAYSIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 344 MALAYSIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 345 MALAYSIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 346 MALAYSIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 347 MALAYSIA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 348 INDONESIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 349 INDONESIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 350 INDONESIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 351 INDONESIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 352 INDONESIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 353 INDONESIA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 354 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 355 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 356 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 357 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 358 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
TABLE 359 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 360 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 361 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 362 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY TYPE, 2024-2031 (USD MILLION)
TABLE 363 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 364 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 365 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
TABLE 366 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 367 BRAZIL: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 368 BRAZIL: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 369 BRAZIL: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 370 BRAZIL: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 371 BRAZIL: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 372 BRAZIL: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 373 MEXICO: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 374 MEXICO: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 375 MEXICO: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 376 MEXICO: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 377 MEXICO: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 378 MEXICO: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 379 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 380 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 381 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 382 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET,BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 383 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET,BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
TABLE 384 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET,BY END USER, 2024-2031 (USD MILLION)
TABLE 385 MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 386 MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 387 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY TYPE, 2024-2031 (USD MILLION)
TABLE 388 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 389 MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 390 MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 391 MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 392 GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 393 GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 394 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY TYPE, 2024-2031 (USD MILLION)
TABLE 395 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 396 GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 397 GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
TABLE 398 GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 399 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 400 SAUDI ARABIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY TYPE, 2024-2031 (USD MILLION)
TABLE 401 SAUDI ARABIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 402 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 403 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 404 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 405 UAE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 406 UAE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE,2024-2031 (USD MILLION)
TABLE 407 UAE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 408 UAE: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 409 UAE: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 410 UAE: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 411 REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET,BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 412 REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 413 REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 414 REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET,BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 415 REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET,BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
TABLE 416 REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET,BY END USER, 2024-2031 (USD MILLION)
TABLE 417 TURKEY: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 418 TURKEY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY TYPE, 2024-2031 (USD MILLION)
TABLE 419 TURKEY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 420 TURKEY: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 421 TURKEY: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 422 TURKEY: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 423 EGYPT: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 424 EGYPT: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 425 EGYPT: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 426 EGYPT: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 427 EGYPT: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 428 EGYPT: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 429 REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 430 REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 431 REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 432 REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 433 REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
TABLE 434 REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 435 AFRICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 436 AFRICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 437 AFRICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 438 AFRICA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 439 AFRICA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 440 AFRICA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 441 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PLASMA FRACTIONATION MARKET, JANUARY 2023-AUGUST 2026
TABLE 442 PLASMA FRACTIONATION MARKET: DEGREE OF COMPETITION
TABLE 443 PLASMA FRACTIONATION MARKET: REGION FOOTPRINT
TABLE 444 PLASMA FRACTIONATION MARKET: PRODUCT FOOTPRINT
TABLE 445 PLASMA FRACTIONATION MARKET: THERAPEUTIC AREA FOOTPRINT
TABLE 446 PLASMA FRACTIONATION MARKET: APPLICATION FOOTPRINT
TABLE 447 PLASMA FRACTIONATION MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 448 PLASMA FRACTIONATION MARKET: COMPETITIVE BENCHMARKING OFKEY STARTUPS/SMES
TABLE 449 PLASMA FRACTIONATION MARKET: PRODUCT LAUNCHES,JANUARY 2023-AUGUST 2026
TABLE 450 PLASMA FRACTIONATION MARKET: DEALS, JANUARY 2023-AUGUST 2026
TABLE 451 PLASMA FRACTIONATION MARKET: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 452 CSL: COMPANY OVERVIEW
TABLE 453 CSL: PRODUCTS OFFERED
TABLE 454 CSL: PRODUCT LAUNCHES, JANUARY 2023-AUGUST 2026
TABLE 455 CSL: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 456 GRIFOLS, S.A.: COMPANY OVERVIEW
TABLE 457 GRIFOLS, S.A.: PRODUCTS OFFERED
TABLE 458 GRIFOLS, S.A.: PRODUCT LAUNCHES, JANUARY 2023-AUGUST 2026
TABLE 459 GRIFOLS, S.A.: DEALS, JANUARY 2023-AUGUST 2026
TABLE 460 GRIFOLS, S.A.: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 461 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
TABLE 462 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED
TABLE 463 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT LAUNCHES,JANUARY 2023-AUGUST 2026
TABLE 464 TAKEDA PHARMACEUTICAL COMPANY LIMITED: DEALS,JANUARY 2023-AUGUST 2026
TABLE 465 TAKEDA PHARMACEUTICAL COMPANY LIMITED: EXPANSIONS,JANUARY 2023-AUGUST 2026
TABLE 466 OCTAPHARMA AG: COMPANY OVERVIEW
TABLE 467 OCTAPHARMA AG: PRODUCTS OFFERED
TABLE 468 OCTAPHARMA AG: PRODUCT LAUNCHES, JANUARY 2023-AUGUST 2026
TABLE 469 OCTAPHARMA AG: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 470 KEDRION S.P.A.: COMPANY OVERVIEW
TABLE 471 KEDRION S.P.A.: PRODUCTS OFFERED
TABLE 472 KEDRION S.P.A.: PRODUCT LAUNCHES, JANUARY 2023-AUGUST 2026
TABLE 473 KEDRION S.P.A.: DEALS, JANUARY 2023-AUGUST 2026
TABLE 474 KEDRION S.P.A.: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 475 LFB: COMPANY OVERVIEW
TABLE 476 LFB: PRODUCTS OFFERED
TABLE 477 LFB: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 478 ADMA BIOLOGICS, INC.: COMPANY OVERVIEW
TABLE 479 ADMA BIOLOGICS, INC.: PRODUCTS OFFERED
TABLE 480 ADMA BIOLOGICS, INC.: DEALS, JANUARY 2023-AUGUST 2026
TABLE 481 SANQUIN: COMPANY OVERVIEW
TABLE 482 SANQUIN: PRODUCTS OFFERED
TABLE 483 SANQUIN: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 484 TAIBANG BIOLOGICAL GROUP CO., LTD.: COMPANY OVERVIEW
TABLE 485 TAIBANG BIOLOGICAL GROUP CO., LTD.: PRODUCTS OFFERED
TABLE 486 TAIBANG BIOLOGICAL GROUP CO., LTD.: EXPANSIONS,JANUARY 2023-AUGUST 2026
TABLE 487 GC BIOPHARMA CORPORATE: COMPANY OVERVIEW
TABLE 488 GC BIOPHARMA CORPORATE: PRODUCTS OFFERED
TABLE 489 GC BIOPHARMA CORPORATE: PRODUCT LAUNCHES,JANUARY 2023-AUGUST 2026
TABLE 490 GC BIOPHARMA CORPORATE: DEALS, JANUARY 2023-AUGUST 2026
TABLE 491 GC BIOPHARMA CORPORATE: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 492 HUALAN BIOLOGICAL ENGINEERING INC.: COMPANY OVERVIEW
TABLE 493 HUALAN BIOLOGICAL ENGINEERING INC.: PRODUCTS OFFERED
TABLE 494 JAPAN BLOOD PRODUCTS ORGANIZATION: COMPANY OVERVIEW
TABLE 495 JAPAN BLOOD PRODUCTS ORGANIZATION: PRODUCTS OFFERED
TABLE 496 JAPAN BLOOD PRODUCTS ORGANIZATION: PRODUCT LAUNCHES,JANUARY 2023-AUGUST 2026
TABLE 497 JAPAN BLOOD PRODUCTS ORGANIZATION: EXPANSIONS,JANUARY 2023-AUGUST 2026
TABLE 498 EMERGENT: COMPANY OVERVIEW
TABLE 499 EMERGENT: PRODUCTS OFFERED
TABLE 500 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: COMPANY OVERVIEW
TABLE 501 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: PRODUCTS OFFERED
TABLE 502 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: DEALS,JANUARY 2023-AUGUST 2026
TABLE 503 INTAS PHARMACEUTICALS LTD.: COMPANY OVERVIEW
TABLE 504 INTAS PHARMACEUTICALS LTD.: PRODUCTS OFFERED
TABLE 505 INTAS PHARMACEUTICALS LTD.: DEALS, JANUARY 2023-AUGUST 2026
TABLE 506 INTAS PHARMACEUTICALS LTD.: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 507 BHARAT SERUMS AND VACCINES LIMITED: COMPANY OVERVIEW
TABLE 508 SK PLASMA: COMPANY OVERVIEW
TABLE 509 SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW
TABLE 510 KAMADA PHARMACEUTICALS: COMPANY OVERVIEW
TABLE 511 CENTURION: COMPANY OVERVIEW
TABLE 512 PLASMAGEN BIOSCIENCES PVT. LTD.: COMPANY OVERVIEW
TABLE 513 VIRCHOW BIOTECH: COMPANY OVERVIEW
TABLE 514 FUSION HEALTHCARE: COMPANY OVERVIEW
TABLE 515 ICHOR: COMPANY OVERVIEW
TABLE 516 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
TABLE 517 RISK ASSESSMENT
TABLE 2 PLASMA FRACTIONATION MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 3 NUMBER OF PLASMA COLLECTION CENTERS, BY COMPANY, 2021-2022
TABLE 4 PLASMA FRACTIONATION MARKET: PORTER’S FIVE FORCES
TABLE 5 PLASMA FRACTIONATION MARKET: ROLE OF PLAYERS IN ECOSYSTEM
TABLE 6 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2023-2025 (USD)
TABLE 7 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025 (USD)
TABLE 8 IMPORT DATA FOR HS CODE 3002.12-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
TABLE 9 EXPORT DATA FOR HS CODE 3002.12-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
TABLE 10 PLASMA FRACTIONATION MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026-MARCH 2027
TABLE 11 RECIPROCAL TARIFF RATES ADJUSTED BY US
TABLE 12 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES
TABLE 13 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2015-2025
TABLE 14 LIST OF KEY PATENTS IN PLASMA FRACTIONATION MARKET, 2023-2025
TABLE 15 CASE STUDIES OF AI IMPLEMENTATION IN PLASMA FRACTIONATION MARKET
TABLE 16 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED PLASMA FRACTIONATION TECHNOLOGIES IN PLASMA FRACTIONATION MARKET
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
TABLE 22 KEY BUYING CRITERIA, BY END USER
TABLE 23 PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 24 PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE,2024-2031 (USD MILLION)
TABLE 25 PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY REGION,2024-2031 (USD MILLION)
TABLE 26 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 27 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 28 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 29 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 30 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 31 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 32 PLASMA FRACTIONATION MARKET FOR IVIG, BY REGION,2024-2031 (USD MILLION)
TABLE 33 PLASMA FRACTIONATION MARKET FOR IVIG, 2024-2031 (METRIC TONS)
TABLE 34 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 35 EUROPE: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 36 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 37 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 38 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 39 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 40 PLASMA FRACTIONATION MARKET FOR SCIG, BY REGION,2024-2031 (USD MILLION)
TABLE 41 PLASMA FRACTIONATION MARKET FOR SCIG, 2024-2031 (METRIC TONS)
TABLE 42 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 43 EUROPE: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 44 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 45 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 46 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 47 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 48 PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY REGION, 2024-2031 (USD MILLION)
TABLE 49 PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS,2024-2031 (METRIC TONS)
TABLE 50 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 51 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 52 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 53 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 54 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 55 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 56 PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 57 PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY REGION, 2024-2031 (USD MILLION)
TABLE 58 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 59 EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 60 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 61 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 62 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 63 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 64 PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY REGION,2024-2031 (USD MILLION)
TABLE 65 PLASMA FRACTIONATION MARKET FOR FACTOR VIII, 2024-2031 (MILLION IU)
TABLE 66 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR VIII,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 67 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 68 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 69 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 70 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 71 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FACTOR VIII,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 72 PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY REGION,2024-2031 (USD MILLION)
TABLE 73 PLASMA FRACTIONATION MARKET FOR FACTOR IX, 2024-2031 (MILLION IU)
TABLE 74 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 75 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 76 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 77 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 78 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 79 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 80 PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY REGION, 2024-2031 (USD MILLION)
TABLE 81 PLASMA FRACTIONATION MARKET FOR FACTOR VON WILLEBRAND FACTOR,2024-2031 (MILLION LITER)
TABLE 82 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 83 EUROPE: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 84 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 85 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 86 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 87 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 88 PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY REGION, 2024-2031 (USD MILLION)
TABLE 89 PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, 2024-2031 (MILLION IU)
TABLE 90 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 91 EUROPE: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 92 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 93 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 94 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 95 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 96 PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY REGION, 2024-2031 (USD MILLION)
TABLE 97 PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES,2024-2031 (MILLION IU)
TABLE 98 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 99 EUROPE: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 100 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 101 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 102 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 103 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 104 PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY REGION,2024-2031 (USD MILLION)
TABLE 105 PLASMA FRACTIONATION MARKET FOR FACTOR XIII, 2024-2031 (MILLION IU)
TABLE 106 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XIII,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 107 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 108 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 109 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 110 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 111 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FACTOR XIII,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 112 PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY REGION, 2024-2031 (USD MILLION)
TABLE 113 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 114 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 115 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 116 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 117 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 118 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 119 PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY REGION,2024-2031 (USD MILLION)
TABLE 120 PLASMA FRACTIONATION MARKET FOR ALBUMIN, 2024-2031 (METRIC TONS)
TABLE 121 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 122 EUROPE: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 123 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 124 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 125 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 126 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 127 PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY REGION,2024-2031 (USD MILLION)
TABLE 128 PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS,2024-2031 (MILLION IU)
TABLE 129 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 130 EUROPE: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 131 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 132 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 133 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 134 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 135 PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY REGION, 2024-2031 (USD MILLION)
TABLE 136 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 137 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 138 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 139 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 140 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 141 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 142 PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 143 PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY REGION,2024-2031 (USD MILLION)
TABLE 144 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 145 EUROPE: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 146 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 147 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 148 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 149 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 150 PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH,BY REGION, 2024-2031 (USD MILLION)
TABLE 151 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 152 EUROPE: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 153 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 154 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 155 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 156 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 157 PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 158 PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY REGION,2024-2031 (USD MILLION)
TABLE 159 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 160 EUROPE: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 161 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 162 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 163 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 164 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR NEUROLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 165 PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY REGION,2024-2031 (USD MILLION)
TABLE 166 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 167 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 168 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 169 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 170 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 171 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 172 PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY REGION,2024-2031 (USD MILLION)
TABLE 173 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 174 EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 175 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 176 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 177 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 178 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 179 PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY REGION,2024-2031 (USD MILLION)
TABLE 180 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 181 EUROPE: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 182 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 183 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 184 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 185 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 186 PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY REGION,2024-2031 (USD MILLION)
TABLE 187 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 188 EUROPE: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 189 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 190 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 191 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 192 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 193 PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY REGION,2024-2031 (USD MILLION)
TABLE 194 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 195 EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 196 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 197 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 198 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 199 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 200 PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY REGION,2024-2031 (USD MILLION)
TABLE 201 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 202 EUROPE: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 203 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 204 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 205 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 206 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 207 PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024-2031 (USD MILLION)
TABLE 208 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 209 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 210 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 211 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 212 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 213 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 214 PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 215 PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS,BY REGION, 2024-2031 (USD MILLION)
TABLE 216 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 217 EUROPE: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 218 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 219 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 220 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 221 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 222 PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 223 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 224 EUROPE: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 225 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 226 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 227 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 228 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 229 PLASMA FRACTIONATION MARKET FOR OTHER END USERS, BY REGION,2024-2031 (USD MILLION)
TABLE 230 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER END USERS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 231 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER END USERS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 232 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER END USERS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 233 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER END USERS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 234 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER END USERS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 235 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER END USERS,BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 236 PLASMA FRACTIONATION MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 237 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 238 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 239 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY TYPE, 2024-2031 (USD MILLION)
TABLE 240 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 241 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 242 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
TABLE 243 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 244 US: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 245 US: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE,2024-2031 (USD MILLION)
TABLE 246 US: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 247 US: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 248 US: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 249 US: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 250 CANADA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 251 CANADA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 252 CANADA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 253 CANADA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 254 CANADA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 255 CANADA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 256 EUROPE: PLASMA FRACTIONATION MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 257 EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 258 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 259 EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 260 EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 261 EUROPE: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 262 EUROPE: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 263 GERMANY: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 264 GERMANY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 265 GERMANY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 266 GERMANY: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 267 GERMANY: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 268 GERMANY: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 269 UK: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 270 UK: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE,2024-2031 (USD MILLION)
TABLE 271 UK: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 272 UK: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 273 UK: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 274 UK: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 275 FRANCE: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 276 FRANCE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 277 FRANCE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 278 FRANCE: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 279 FRANCE: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 280 FRANCE: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 281 ITALY: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 282 ITALY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 283 ITALY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 284 ITALY: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 285 ITALY: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 286 ITALY: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 287 SPAIN: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 288 SPAIN: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 289 SPAIN: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 290 SPAIN: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 291 SPAIN: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 292 SPAIN: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 293 REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 294 REST OF EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY TYPE, 2024-2031 (USD MILLION)
TABLE 295 REST OF EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 296 REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 297 REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
TABLE 298 REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 299 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 300 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 301 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY TYPE, 2024-2031 (USD MILLION)
TABLE 302 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 303 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 304 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 305 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 306 CHINA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 307 CHINA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 308 CHINA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 309 CHINA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 310 CHINA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 311 CHINA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 312 JAPAN: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 313 JAPAN: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 314 JAPAN: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 315 JAPAN: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 316 JAPAN: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 317 JAPAN: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 318 INDIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 319 INDIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 320 INDIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 321 INDIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 322 INDIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 323 INDIA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 324 SOUTH KOREA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 325 SOUTH KOREA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY TYPE, 2024-2031 (USD MILLION)
TABLE 326 SOUTH KOREA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 327 SOUTH KOREA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 328 SOUTH KOREA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 329 SOUTH KOREA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 330 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 331 AUSTRALIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 332 AUSTRALIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 333 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 334 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 335 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 336 VIETNAM: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 337 VIETNAM: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 338 VIETNAM: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 339 VIETNAM: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 340 VIETNAM: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 341 VIETNAM: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 342 MALAYSIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 343 MALAYSIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 344 MALAYSIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 345 MALAYSIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 346 MALAYSIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 347 MALAYSIA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 348 INDONESIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 349 INDONESIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 350 INDONESIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 351 INDONESIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 352 INDONESIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 353 INDONESIA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 354 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 355 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 356 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 357 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 358 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
TABLE 359 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 360 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 361 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 362 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY TYPE, 2024-2031 (USD MILLION)
TABLE 363 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 364 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 365 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
TABLE 366 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 367 BRAZIL: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 368 BRAZIL: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 369 BRAZIL: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 370 BRAZIL: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 371 BRAZIL: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 372 BRAZIL: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 373 MEXICO: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 374 MEXICO: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 375 MEXICO: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 376 MEXICO: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 377 MEXICO: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 378 MEXICO: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 379 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 380 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 381 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 382 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET,BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 383 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET,BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
TABLE 384 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET,BY END USER, 2024-2031 (USD MILLION)
TABLE 385 MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 386 MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 387 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY TYPE, 2024-2031 (USD MILLION)
TABLE 388 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 389 MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 390 MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 391 MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 392 GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY COUNTRY,2024-2031 (USD MILLION)
TABLE 393 GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 394 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY TYPE, 2024-2031 (USD MILLION)
TABLE 395 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 396 GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 397 GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
TABLE 398 GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 399 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 400 SAUDI ARABIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY TYPE, 2024-2031 (USD MILLION)
TABLE 401 SAUDI ARABIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 402 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 403 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 404 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 405 UAE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 406 UAE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE,2024-2031 (USD MILLION)
TABLE 407 UAE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 408 UAE: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 409 UAE: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 410 UAE: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 411 REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET,BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 412 REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 413 REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 414 REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET,BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 415 REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET,BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
TABLE 416 REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET,BY END USER, 2024-2031 (USD MILLION)
TABLE 417 TURKEY: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 418 TURKEY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS,BY TYPE, 2024-2031 (USD MILLION)
TABLE 419 TURKEY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 420 TURKEY: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 421 TURKEY: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 422 TURKEY: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 423 EGYPT: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 424 EGYPT: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 425 EGYPT: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 426 EGYPT: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 427 EGYPT: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 428 EGYPT: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 429 REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 430 REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 431 REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 432 REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 433 REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
TABLE 434 REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 435 AFRICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,2024-2031 (USD MILLION)
TABLE 436 AFRICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 437 AFRICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 438 AFRICA: PLASMA FRACTIONATION MARKET, BY APPLICATION,2024-2031 (USD MILLION)
TABLE 439 AFRICA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA,2024-2031 (USD MILLION)
TABLE 440 AFRICA: PLASMA FRACTIONATION MARKET, BY END USER,2024-2031 (USD MILLION)
TABLE 441 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PLASMA FRACTIONATION MARKET, JANUARY 2023-AUGUST 2026
TABLE 442 PLASMA FRACTIONATION MARKET: DEGREE OF COMPETITION
TABLE 443 PLASMA FRACTIONATION MARKET: REGION FOOTPRINT
TABLE 444 PLASMA FRACTIONATION MARKET: PRODUCT FOOTPRINT
TABLE 445 PLASMA FRACTIONATION MARKET: THERAPEUTIC AREA FOOTPRINT
TABLE 446 PLASMA FRACTIONATION MARKET: APPLICATION FOOTPRINT
TABLE 447 PLASMA FRACTIONATION MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 448 PLASMA FRACTIONATION MARKET: COMPETITIVE BENCHMARKING OFKEY STARTUPS/SMES
TABLE 449 PLASMA FRACTIONATION MARKET: PRODUCT LAUNCHES,JANUARY 2023-AUGUST 2026
TABLE 450 PLASMA FRACTIONATION MARKET: DEALS, JANUARY 2023-AUGUST 2026
TABLE 451 PLASMA FRACTIONATION MARKET: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 452 CSL: COMPANY OVERVIEW
TABLE 453 CSL: PRODUCTS OFFERED
TABLE 454 CSL: PRODUCT LAUNCHES, JANUARY 2023-AUGUST 2026
TABLE 455 CSL: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 456 GRIFOLS, S.A.: COMPANY OVERVIEW
TABLE 457 GRIFOLS, S.A.: PRODUCTS OFFERED
TABLE 458 GRIFOLS, S.A.: PRODUCT LAUNCHES, JANUARY 2023-AUGUST 2026
TABLE 459 GRIFOLS, S.A.: DEALS, JANUARY 2023-AUGUST 2026
TABLE 460 GRIFOLS, S.A.: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 461 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
TABLE 462 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED
TABLE 463 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT LAUNCHES,JANUARY 2023-AUGUST 2026
TABLE 464 TAKEDA PHARMACEUTICAL COMPANY LIMITED: DEALS,JANUARY 2023-AUGUST 2026
TABLE 465 TAKEDA PHARMACEUTICAL COMPANY LIMITED: EXPANSIONS,JANUARY 2023-AUGUST 2026
TABLE 466 OCTAPHARMA AG: COMPANY OVERVIEW
TABLE 467 OCTAPHARMA AG: PRODUCTS OFFERED
TABLE 468 OCTAPHARMA AG: PRODUCT LAUNCHES, JANUARY 2023-AUGUST 2026
TABLE 469 OCTAPHARMA AG: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 470 KEDRION S.P.A.: COMPANY OVERVIEW
TABLE 471 KEDRION S.P.A.: PRODUCTS OFFERED
TABLE 472 KEDRION S.P.A.: PRODUCT LAUNCHES, JANUARY 2023-AUGUST 2026
TABLE 473 KEDRION S.P.A.: DEALS, JANUARY 2023-AUGUST 2026
TABLE 474 KEDRION S.P.A.: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 475 LFB: COMPANY OVERVIEW
TABLE 476 LFB: PRODUCTS OFFERED
TABLE 477 LFB: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 478 ADMA BIOLOGICS, INC.: COMPANY OVERVIEW
TABLE 479 ADMA BIOLOGICS, INC.: PRODUCTS OFFERED
TABLE 480 ADMA BIOLOGICS, INC.: DEALS, JANUARY 2023-AUGUST 2026
TABLE 481 SANQUIN: COMPANY OVERVIEW
TABLE 482 SANQUIN: PRODUCTS OFFERED
TABLE 483 SANQUIN: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 484 TAIBANG BIOLOGICAL GROUP CO., LTD.: COMPANY OVERVIEW
TABLE 485 TAIBANG BIOLOGICAL GROUP CO., LTD.: PRODUCTS OFFERED
TABLE 486 TAIBANG BIOLOGICAL GROUP CO., LTD.: EXPANSIONS,JANUARY 2023-AUGUST 2026
TABLE 487 GC BIOPHARMA CORPORATE: COMPANY OVERVIEW
TABLE 488 GC BIOPHARMA CORPORATE: PRODUCTS OFFERED
TABLE 489 GC BIOPHARMA CORPORATE: PRODUCT LAUNCHES,JANUARY 2023-AUGUST 2026
TABLE 490 GC BIOPHARMA CORPORATE: DEALS, JANUARY 2023-AUGUST 2026
TABLE 491 GC BIOPHARMA CORPORATE: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 492 HUALAN BIOLOGICAL ENGINEERING INC.: COMPANY OVERVIEW
TABLE 493 HUALAN BIOLOGICAL ENGINEERING INC.: PRODUCTS OFFERED
TABLE 494 JAPAN BLOOD PRODUCTS ORGANIZATION: COMPANY OVERVIEW
TABLE 495 JAPAN BLOOD PRODUCTS ORGANIZATION: PRODUCTS OFFERED
TABLE 496 JAPAN BLOOD PRODUCTS ORGANIZATION: PRODUCT LAUNCHES,JANUARY 2023-AUGUST 2026
TABLE 497 JAPAN BLOOD PRODUCTS ORGANIZATION: EXPANSIONS,JANUARY 2023-AUGUST 2026
TABLE 498 EMERGENT: COMPANY OVERVIEW
TABLE 499 EMERGENT: PRODUCTS OFFERED
TABLE 500 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: COMPANY OVERVIEW
TABLE 501 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: PRODUCTS OFFERED
TABLE 502 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: DEALS,JANUARY 2023-AUGUST 2026
TABLE 503 INTAS PHARMACEUTICALS LTD.: COMPANY OVERVIEW
TABLE 504 INTAS PHARMACEUTICALS LTD.: PRODUCTS OFFERED
TABLE 505 INTAS PHARMACEUTICALS LTD.: DEALS, JANUARY 2023-AUGUST 2026
TABLE 506 INTAS PHARMACEUTICALS LTD.: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 507 BHARAT SERUMS AND VACCINES LIMITED: COMPANY OVERVIEW
TABLE 508 SK PLASMA: COMPANY OVERVIEW
TABLE 509 SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW
TABLE 510 KAMADA PHARMACEUTICALS: COMPANY OVERVIEW
TABLE 511 CENTURION: COMPANY OVERVIEW
TABLE 512 PLASMAGEN BIOSCIENCES PVT. LTD.: COMPANY OVERVIEW
TABLE 513 VIRCHOW BIOTECH: COMPANY OVERVIEW
TABLE 514 FUSION HEALTHCARE: COMPANY OVERVIEW
TABLE 515 ICHOR: COMPANY OVERVIEW
TABLE 516 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
TABLE 517 RISK ASSESSMENT
LIST OF FIGURES
FIGURE 1 PLASMA FRACTIONATION MARKET SEGMENTATION & REGIONS CONSIDERED
FIGURE 2 PLASMA FRACTIONATION MARKET: YEARS CONSIDERED
FIGURE 3 MARKET SCENARIO
FIGURE 4 GLOBAL PLASMA FRACTIONATION MARKET, 2024-2031
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PLASMA FRACTIONATION MARKET, 2023-2026
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF PLASMA FRACTIONATION MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS IN PLASMA FRACTIONATION MARKET, 2026-2031
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PLASMA FRACTIONATION MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 9 RISING ADOPTION OF PLASMA-DERIVED PRODUCTS IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET GROWTH
FIGURE 10 THERAPEUTICS ACCOUNTED FOR LARGEST SHARE OF PLASMA FRACTIONATION MARKET IN NORTH AMERICA IN 2025
FIGURE 11 CHINA AND GERMANY LIKELY TO BE FASTEST-GROWING MARKETS INGLOBAL PLASMA FRACTIONATION MARKET DURING FORECAST PERIOD
FIGURE 12 THERAPEUTICS TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 13 PLASMA FRACTIONATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,AND CHALLENGES
FIGURE 14 PLASMA FRACTIONATION MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 15 PLASMA FRACTIONATION MARKET: VALUE CHAIN ANALYSIS
FIGURE 16 PLASMA FRACTIONATION MARKET: ECOSYSTEM ANALYSIS
FIGURE 17 AVERAGE SELLING PRICE OF PRODUCTS, 2025 (USD)
FIGURE 18 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2025 (USD)
FIGURE 19 PLASMA FRACTIONATION MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 20 INVESTMENT & FUNDING SCENARIO, 2024-2026 (USD MILLION)
FIGURE 21 PATENT APPLICATIONS IN PLASMA FRACTIONATION MARKET,JANUARY 2015-DECEMBER 2025
FIGURE 22 IMPACT OF AI/GEN AI ON PLASMA FRACTIONATION MARKET
FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
FIGURE 24 KEY BUYING CRITERIA, BY END USER
FIGURE 25 NORTH AMERICA: PLASMA FRACTIONATION MARKET SNAPSHOT
FIGURE 26 ASIA PACIFIC: PLASMA FRACTIONATION MARKET SNAPSHOT
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN PLASMA FRACTIONATION MARKET, 2021-2025 (USD MILLION)
FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PLASMA FRACTIONATIONMARKET, 2025
FIGURE 29 PLASMA FRACTIONATION MARKET: COMPANY EVALUATION MATRIX(KEY PLAYERS), 2025
FIGURE 30 PLASMA FRACTIONATION MARKET: COMPANY FOOTPRINT
FIGURE 31 PLASMA FRACTIONATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETAOF KEY VENDORS
FIGURE 33 EV/EBITDA OF KEY VENDORS
FIGURE 34 PLASMA FRACTIONATION MARKET: BRAND/PRODUCT COMPARISON
FIGURE 35 CSL: COMPANY SNAPSHOT (2025)
FIGURE 36 GRIFOLS, S.A.: COMPANY SNAPSHOT (2025)
FIGURE 37 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2025)
FIGURE 38 OCTAPHARMA AG: COMPANY SNAPSHOT (2025)
FIGURE 39 KEDRION S.P.A.: COMPANY SNAPSHOT (2025)
FIGURE 40 ADMA BIOLOGICS, INC.: COMPANY SNAPSHOT (2025)
FIGURE 41 SANQUIN: COMPANY SNAPSHOT (2025)
FIGURE 42 GC BIOPHARMA CORPORATE: COMPANY SNAPSHOT (2025)
FIGURE 43 EMERGENT: COMPANY SNAPSHOT (2025)
FIGURE 44 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 45 PLASMA FRACTIONATION MARKET: RESEARCH DESIGN
FIGURE 46 PLASMA FRACTIONATION MARKET: BREAKDOWN OF PRIMARIES
FIGURE 47 PLASMA FRACTIONATION MARKET: INSIGHTS FROM PRIMARIES
FIGURE 48 GLOBAL PLASMA FRACTIONATION MARKET ESTIMATION, 2025
FIGURE 49 PLASMA FRACTIONATION MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025)
FIGURE 50 ILLUSTRATIVE EXAMPLE OF CSL: REVENUE ANALYSIS (2025)
FIGURE 51 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 52 PLASMA FRACTIONATION MARKET: CAGR PROJECTIONS
FIGURE 53 PLASMA FRACTIONATION MARKET: DATA TRIANGULATION
FIGURE 2 PLASMA FRACTIONATION MARKET: YEARS CONSIDERED
FIGURE 3 MARKET SCENARIO
FIGURE 4 GLOBAL PLASMA FRACTIONATION MARKET, 2024-2031
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PLASMA FRACTIONATION MARKET, 2023-2026
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF PLASMA FRACTIONATION MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS IN PLASMA FRACTIONATION MARKET, 2026-2031
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PLASMA FRACTIONATION MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 9 RISING ADOPTION OF PLASMA-DERIVED PRODUCTS IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET GROWTH
FIGURE 10 THERAPEUTICS ACCOUNTED FOR LARGEST SHARE OF PLASMA FRACTIONATION MARKET IN NORTH AMERICA IN 2025
FIGURE 11 CHINA AND GERMANY LIKELY TO BE FASTEST-GROWING MARKETS INGLOBAL PLASMA FRACTIONATION MARKET DURING FORECAST PERIOD
FIGURE 12 THERAPEUTICS TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 13 PLASMA FRACTIONATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,AND CHALLENGES
FIGURE 14 PLASMA FRACTIONATION MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 15 PLASMA FRACTIONATION MARKET: VALUE CHAIN ANALYSIS
FIGURE 16 PLASMA FRACTIONATION MARKET: ECOSYSTEM ANALYSIS
FIGURE 17 AVERAGE SELLING PRICE OF PRODUCTS, 2025 (USD)
FIGURE 18 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2025 (USD)
FIGURE 19 PLASMA FRACTIONATION MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 20 INVESTMENT & FUNDING SCENARIO, 2024-2026 (USD MILLION)
FIGURE 21 PATENT APPLICATIONS IN PLASMA FRACTIONATION MARKET,JANUARY 2015-DECEMBER 2025
FIGURE 22 IMPACT OF AI/GEN AI ON PLASMA FRACTIONATION MARKET
FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
FIGURE 24 KEY BUYING CRITERIA, BY END USER
FIGURE 25 NORTH AMERICA: PLASMA FRACTIONATION MARKET SNAPSHOT
FIGURE 26 ASIA PACIFIC: PLASMA FRACTIONATION MARKET SNAPSHOT
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN PLASMA FRACTIONATION MARKET, 2021-2025 (USD MILLION)
FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PLASMA FRACTIONATIONMARKET, 2025
FIGURE 29 PLASMA FRACTIONATION MARKET: COMPANY EVALUATION MATRIX(KEY PLAYERS), 2025
FIGURE 30 PLASMA FRACTIONATION MARKET: COMPANY FOOTPRINT
FIGURE 31 PLASMA FRACTIONATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETAOF KEY VENDORS
FIGURE 33 EV/EBITDA OF KEY VENDORS
FIGURE 34 PLASMA FRACTIONATION MARKET: BRAND/PRODUCT COMPARISON
FIGURE 35 CSL: COMPANY SNAPSHOT (2025)
FIGURE 36 GRIFOLS, S.A.: COMPANY SNAPSHOT (2025)
FIGURE 37 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2025)
FIGURE 38 OCTAPHARMA AG: COMPANY SNAPSHOT (2025)
FIGURE 39 KEDRION S.P.A.: COMPANY SNAPSHOT (2025)
FIGURE 40 ADMA BIOLOGICS, INC.: COMPANY SNAPSHOT (2025)
FIGURE 41 SANQUIN: COMPANY SNAPSHOT (2025)
FIGURE 42 GC BIOPHARMA CORPORATE: COMPANY SNAPSHOT (2025)
FIGURE 43 EMERGENT: COMPANY SNAPSHOT (2025)
FIGURE 44 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 45 PLASMA FRACTIONATION MARKET: RESEARCH DESIGN
FIGURE 46 PLASMA FRACTIONATION MARKET: BREAKDOWN OF PRIMARIES
FIGURE 47 PLASMA FRACTIONATION MARKET: INSIGHTS FROM PRIMARIES
FIGURE 48 GLOBAL PLASMA FRACTIONATION MARKET ESTIMATION, 2025
FIGURE 49 PLASMA FRACTIONATION MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025)
FIGURE 50 ILLUSTRATIVE EXAMPLE OF CSL: REVENUE ANALYSIS (2025)
FIGURE 51 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 52 PLASMA FRACTIONATION MARKET: CAGR PROJECTIONS
FIGURE 53 PLASMA FRACTIONATION MARKET: DATA TRIANGULATION
